SOPHiA GENETICS announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) and AstraZeneca to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide. Cancer is the second leading cause of death worldwide.

In 2020, 10 million deaths were attributed to cancer, 70% of which occurred in low- and middle-income countries. While there are multifaceted reasons for this disparity, a top contributor is the lack of adequate testing, which can lead to prevention, early detection, and advanced treatment. Through the newly announced partnership, SOPHiA GENETICS, MSK, and AstraZeneca will create a decentralized global network for cancer testing, including underserved regions where access to testing remains scarce.

The partnership will provide MSK's proprietary liquid biopsy and solid tumor cancer tests ? MSK-ACCESS® and MSK-IMPACT® ? to organizations via the decentralized, technology-agnostic SOPHiA DDM?

Platform. This offering will be rapidly deployed by SOPHiA GENETICS with support from AstraZeneca's global footprint. Through SOPHiA GENETICS' cloud-based platform, which provides highly accurate and reliable data and insights, institutions around the world ?

and in traditionally under-resourced and under-served areas ? will have the power to make data-driven decisions. This collaboration aims to generate an unparalleled and comprehensive dataset sourced from diverse populations to provide invaluable insights and knowledge that could shape the future of global healthcare.